الفهرس 
Aim of The WorkOnly 14 pages are availabe for public view
 |  | from | 123 |  |  |
| | | from | 123 | | |
Abstract
Neuropeptide Y1 Receptor (NPY1R) is one of the most abundant
peptides in the central and peripheral nervous systems of mammals. It has
been found to play a role in various physiological functions. Besides, it
has been shown to promote proliferation, vascularization and stimulate
migration in several cell types and tissues. This is particularly important
in malignant tissues, where NPY1R expression may have a prognostic
value in the natural history of the disease.
The aims of this study were to detect the expression of NPY1R in
patients with breast cancer and to assess its correlation with different
clinicopathological variables as well as previously known prognostic
factors.
The study was conducted at Clinical Oncology Department,
Menoufia University recruiting patients diagnosed between January 2015
and December 2017. Clinical and pathological data of included patients
were extracted from patients’ medical records. Formalin-fixed paraffinembedded
blocks of corresponding patients were collected and were
subject to further immunohistochemistry for detection of NPY1R
expression.
Ninety-two cases with median age of 51.5 years were included in
the final data analysis, most of whom had a pathological diagnosis of
invasive duct carcinoma (95.7%). Neuropeptide Y1 Receptor (NPY1R)
tested positive in 50% of malignant cases (n = 46). When we tested
NPY1R in different types of tissues, NPY1R was found to be statistically
more common in invasive and DCIS cases compared with non-neoplastic
cases (50% and 53.3% versus 20.7%; p = 0.002 and p = <0.001,
respectively).
Statistically significant associations were found between NPY1R
expression and presence of metastatic disease, stage, ER expression,
molecular subtype, NPI risk group, type of surgery, radiotherapy
treatment, hormonal treatment, and type of endocrine therapy. On the
other hand, no significant associations could be identified with tumor
size, pathology type, patient’s age, lymph node metastases, PR, and
her2/neu overexpression. Median OS and median PFS were not reached
in both NPY1R positive and NPY1R negative groups, with no statistical
difference between the two cohorts.
Conclusion:
NPY1R is not uncommon, being present in about 50% of
malignant breast cancer cases. Its expression has been found to correlate
with some features of aggressive disease suggesting a potential
prognostic role of the marker in breast cancer.